Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Stoof

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1997
Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PETG Tissingh, P Bergmans, A Winogrodzka, et al.
European Journal of Nuclear Medicine|September 8, 1997
[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controlsG Tissingh, P Bergmans, J Booij, et al.
Neuroreport|July 29, 1996
Presence of glutathione immunoreactivity in cultured neurones and astrocytesC H Langeveld, E Schepens, C A Jongenelen, et al.
Psychopharmacology|April 1, 1995
Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
Annals of Neurology|July 18, 2001
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smellH W Berendse, J Booij, C M Francot, et al.
The European Journal of Neuroscience|September 6, 2000
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigraG Andringa, R V van Oosten, W Unger, et al.
European Journal of Nuclear Medicine|January 1, 1997
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's diseaseJ Booij, G Tissingh, A Winogrodzka, et al.
European Journal of Pharmacology|October 9, 1990
Lack of a dopamine autoreceptor selective profile of B-HT 920 in functional in vitro model systems of D2 receptors in rat striatumB Drukarch, E Schepens, M J Dolleman-Van der Weel, et al.
European Journal of Pharmacology|August 12, 1999
Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacyJ C Stoof, A Winogrodzka, F L van Muiswinkel, et al.
Biochemical Pharmacology|January 24, 1997
The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kineticsC H Langeveld, C A Jongenelen, J W Theeuwes, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1997
Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PETG Tissingh, P Bergmans, A Winogrodzka, et al.
European Journal of Nuclear Medicine|September 8, 1997
[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controlsG Tissingh, P Bergmans, J Booij, et al.
Neuroreport|July 29, 1996
Presence of glutathione immunoreactivity in cultured neurones and astrocytesC H Langeveld, E Schepens, C A Jongenelen, et al.
Psychopharmacology|April 1, 1995
Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
Annals of Neurology|July 18, 2001
Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smellH W Berendse, J Booij, C M Francot, et al.
The European Journal of Neuroscience|September 6, 2000
Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigraG Andringa, R V van Oosten, W Unger, et al.
European Journal of Nuclear Medicine|January 1, 1997
Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's diseaseJ Booij, G Tissingh, A Winogrodzka, et al.
European Journal of Pharmacology|October 9, 1990
Lack of a dopamine autoreceptor selective profile of B-HT 920 in functional in vitro model systems of D2 receptors in rat striatumB Drukarch, E Schepens, M J Dolleman-Van der Weel, et al.
European Journal of Pharmacology|August 12, 1999
Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacyJ C Stoof, A Winogrodzka, F L van Muiswinkel, et al.
Biochemical Pharmacology|January 24, 1997
The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kineticsC H Langeveld, C A Jongenelen, J W Theeuwes, et al.
Pageof 12